Paolo Tarantino/X
Apr 21, 2025, 16:15
Paolo Tarantino: T-DXd with Pertuzumab improves PFS vs THP in first-line HER2+ mBC
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Press release: T-DXd + pertuzumab improved PFS vs THP in first-line HER2+ mBC. The T-DXd monotherapy arm remains blinded.
The PFS advantage with T-DXd+P is likely to be considerable. Enough to convince breast med oncs to drop the taxane induction strategy?”
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 16:16
May 10, 2025, 16:04
May 10, 2025, 15:50
May 10, 2025, 15:35